11. 重症筋無力症 Myasthenia gravis Clinical trials / Disease details

臨床試験数 : 315 / 薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04182984 (ClinicalTrials.gov)	November 4, 2019	26/11/2019	TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-w ...	TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-w ...	Ocular Myasthenia Gravis	Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycopheno ...	Tang-Du Hospital	NULL	Recruiting	18 Years	75 Years	All	200		China
2	NCT03490539 (ClinicalTrials.gov)	May 7, 2018	21/3/2018	Disease-Modifying Treatments for Myasthenia Gravis	Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-modifying ...	Neurological Disorder;Autoimmune Diseases	Drug: Mycophenolate Mofetil;Drug: Azathioprine	Duke University	Beth Israel Deaconess Medical Center;Patient-Centered Outcomes Research Institute	Completed	18 Years	N/A	All	167		United States;Canada
3	EUCTR2005-000343-28-IT (EUCTR)	29/03/2006	15/03/2006	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	Myasthenia Gravis MedDRA version: 6.1;Level: PT;Classification code 10028417	Trade Name: cellcept INN or Proposed INN: Mycophenolic acid	ASPREVA PHARMACEUTICALS CORPORATION	NULL	Not Recruiting			Female: yes Male: yes	136		United Kingdom;Germany;Spain;Italy
4	EUCTR2005-000343-28-DE (EUCTR)	19/12/2005	10/05/2005	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	Myasthenia Gravis MedDRA version: 8.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis ...	Trade Name: Cellcept 500 mg tablets Product Name: CellCept 500 mg tablets INN or Proposed INN: mycophe ...	Aspreva Pharmaceuticals Corporation	NULL	Not Recruiting			Female: yes Male: yes	136		Spain;Germany;Italy;United Kingdom
5	EUCTR2004-000596-34-HU (EUCTR)	30/09/2005	08/06/2005	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	Myasthenia gravis MedDRA version: 7;Level: PT;Classification code 10028417	Trade Name: CellCept®500 mg tablets Product Name: CellCept 500 mg film-coated tablets INN or Proposed ...	F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program	NULL	Not Recruiting			Female: yes Male: yes	136		Hungary;Czech Republic;Spain;Italy
6	EUCTR2005-000343-28-GB (EUCTR)	05/09/2005	28/06/2005	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	An optional continuation of double-blind treatment for subjects who have achieved good symptom contr ...	Myasthenia Gravis MedDRA version: 7;Level: PT;Classification code 10028417	Product Name: CellCept 500 mg tablets INN or Proposed INN: mycophenolate mofetil	Aspreva Pharmaceutical Corporation	NULL	Not Recruiting			Female: yes Male: yes	136		Germany;United Kingdom;Spain;Italy
7	EUCTR2004-000596-34-ES (EUCTR)	01/09/2005	05/07/2005	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	Myasthenia gravis MedDRA version: 7;Level: PT;Classification code 10028417	Trade Name: CellCept®500 mg tablets Product Name: CellCept 500 mg film-coated tablets INN or Proposed ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting			Female: yes Male: yes	136	Phase 3	Hungary;Czech Republic;Spain;Italy
8	EUCTR2004-000596-34-IT (EUCTR)	01/06/2005	20/06/2005	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week tr ...	Myastenia gravis MedDRA version: 6.1;Level: PT;Classification code 10028417	Trade Name: CELLCEPT INN or Proposed INN: Mycophenolic acid	ASPREVA PHARMACEUTICALS CORPORATION	NULL	Not Recruiting			Female: yes Male: yes	136		Hungary;Czech Republic;Spain;Italy
9	EUCTR2004-000596-34-CZ (EUCTR)	19/05/2005	06/05/2005	A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks t ...	A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks t ...	Myasthenia gravis MedDRA version: 7.1;Level: LLT;Classification code 10028417	Trade Name: CellCept 500 mg Product Name: CellCept	F.Hoffmann-La Roche Ltd.	NULL	Not Recruiting			Female: yes Male: yes	136		Hungary;Czech Republic;Spain;Italy
10	NCT00683969 (ClinicalTrials.gov)	August 2004	19/5/2008	A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Cont ...	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Tr ...	Myasthenia Gravis, Generalized	Drug: mycophenolate mofetil (CellCept);Drug: placebo	Hoffmann-La Roche	Aspreva Pharmaceuticals	Completed	18 Years	80 Years	Both	136	Phase 3	United States;Canada;Former Serbia and Montenegro;France;Germany;India;Israel;Italy;Mexico;Netherlan ...

First Previous1 2Next Last